Josu de la Fuente/imperial.nhs.uk
Apr 5, 2026, 17:42
Josu de la Fuente: Real World Data Shows Significant Risk of Subsequent HCT in SCD and Thalassemia
Josu de la Fuente, Consultant Paediatric Haematologist Director Blood and Marrow Transplant Programme at Imperial College Healthcare NHS Trust, shared a post on LinkedIn:
“Real-world data confirms a small but significant risk of the need for a subsequent HCT with no plateau over time in sickle and thalassaemia.
Real world data from HWP of EBMT presented today.”
Stay updated with Hemostasis Today.
-
Jun 1, 2026, 13:44Milad Abdalla: Elevating Phlebotomy Standards – Why Order of Draw and Blood Cultures Matter
-
Jun 1, 2026, 13:39Abdul Mannan: The Moral Injury of Practising Haemato-Oncology in a Resource-Limited Setting
-
Jun 1, 2026, 13:34Filza Aslam: What Does a Patient Journey Partner Actually Do in Bleeding Disorders?
-
Jun 1, 2026, 13:33Darine Ghanem: Advancing Health Equity in Care at the LATAM Meeting
-
Jun 1, 2026, 13:23Skye Collado: Miller-Keystone Blood Center Expands Community Impact Through the Addition of New Bloodmobiles
-
Jun 1, 2026, 12:37Rutuja Mahadik: Anemia is More Than Just Feeling Tired
-
Jun 1, 2026, 12:36Ankur Jindal: Large-Vessel Inflammation and Immune Dysregulation in Wiskott–Aldrich Syndrome
-
Jun 1, 2026, 12:35Shadi Almassri: Conditions That Can Cause False High or False Low HbA1c Results
-
Jun 1, 2026, 12:22Ed Davidson: Clot Removing Technology That Can Change the Game